Daiichi Sankyo España company information, Employees & Contact Information

WCLC: Daiichi’s I-DXd shows 48.2% ORR in ES-SCLC trial Clinical Trials Arena

AstraZeneca, Daiichi Sankyo succeed in late-stage breast cancer study Seeking Alpha

Merck & Co., (MRK) and Daiichi Sankyo Announces Positive Results for Ifinatamab deruxtecan Insider Monkey

Merck, Daiichi Sankyo Stage Lung Cancer Rally With ‘Strong’ Pivotal Data for I-Dxd BioSpace

Daiichi Sankyo struck gold with ‘ADC’ cancer drugs. Its new CEO has to figure out what’s next. BioPharma Dive

Daiichi Sankyo is leveraging Azure OpenAI Service to develop generative AI and foster an AI-friendly culture Microsoft

Daiichi Sankyo/Merck’s I-Dxd Tipped For Fast Track After Lung Cancer Results Citeline News & Insights

Daiichi Sankyo celebrates its roots and blooming future at DC cherry blossom festival Fierce Pharma

WCLC25: Merck & Co., Daiichi's B7-H3 directed ADC shows 48% response in hard-to-treat lung cancer FirstWord Pharma

Daiichi Sankyo buys solid tumour ADC from Glycotope for $132.5m Pharmaceutical Technology

Daiichi Sankyo Presents New Data in Small Cell Lung Cancer and Updates Across ADC Portfolio Highlighting Progress in Creating New Standards of Care for Patients with Lung Cancer at WCLC BioSpace

AstraZeneca, Daiichi Sankyo under priority review of FDA for breast cancer Seeking Alpha

Daiichi Sankyo, AstraZeneca's highly touted ADC Datroway off to 'smooth market launch' Fierce Pharma

IHH Healthcare arm increases damages sought from Daiichi Sankyo to ₹11,800 crore over Fortis stake dispute Mint

Daiichi Sankyo Establishes Third Research Institute in San Diego Yahoo Finance

Merck, Daiichi Sankyo Pull Lung Cancer Filing for ADC, Citing Underwhelming Survival Findings BioSpace

Daiichi Sankyo (TSE:4568): Exploring Valuation After Recent Share Price Uptick Yahoo Finance

Hiroyuki Okuzawa succeeds Sunao Manabe as Daiichi Sankyo CEO Pharmaceutical Technology

Daiichi Sankyo links up with Korea's Alteogen on subcutaneous Enhertu in $300M licensing deal Fierce Pharma

After Tough 2024, AstraZeneca/Daiichi Sankyo Push Enters Key Period BioSpace

AstraZeneca/Daiichi Sankyo Partnered Breast Cancer Drug Shows Survival Benefit Over Chemotherapy Yahoo Finance

Merck and Daiichi Sankyo’s I-DXd Earns FDA Breakthrough Therapy Status in Small Cell Lung Cancer BioPharm International

Wayfinder Biosciences and Daiichi Sankyo collaborate to develop novel RNA-targeting therapies for neurodegenerative disease PR Newswire

MSD signs Daiichi Sankyo in multibillion dollar deal to develop ADCs Pharmaceutical Technology

Japanese health care firm Daiichi Sankyo acquires sports nutrition brand DNS NutraIngredients.com

Daiichi Sankyo: Good Diversification Tool For U.S. Investors Seeking Alpha

AstraZeneca, Daiichi Sankyo Push Enhertu to Frontline Breast Cancer With Phase III Data BioSpace

Daiichi Sankyo to absorb manufacturing units in move to leverage ADC strength Fierce Pharma

Daiichi Sankyo Admits 2024 Wasn’t ‘Perfect’ but 2025 Is Starting Off With a Bang BioSpace

Daiichi Sankyo builds $152M ADC plant in China as Enhertu wins national coverage Fierce Pharma

How Daiichi Sankyo Europe drives growth with digital and analytics McKinsey & Company

Daiichi Sankyo tipped to dominate antibody-drug conjugate market through 2029 Fierce Pharma

Daiichi Sankyo plots €1B expansion to beef up antibody-drug conjugate production in Germany Fierce Pharma

AstraZeneca/Daiichi Sankyo survey reveals breast cancer misconceptions in Europe PMLiVE

Daiichi Sankyo Drops $1B to Boost ADC Manufacturing Capacity at German Site BioSpace

Daiichi Sankyo Again Raises Enhertu Sales Forecast Driven by Non-US Growth BioSpace

Daiichi Sankyo scores $182M from Novartis settlement in long-running patent case Fierce Pharma

Immuto Scientific Announces $8M Seed 2 Financing and Daiichi Sankyo Collaboration to Uncover a New Class of Therapeutic Targets with Structural Surfaceomics Business Wire

Daiichi Sankyo bags an industry first with Japanese nod for blood cancer drug Ezharmia Fierce Pharma

Without Pfizer appeal, Daiichi Sankyo closes long-running ADC patent arbitration with $47M win Fierce Pharma

High Expectations And Data Disappointments Have Driven Daiichi Sankyo Lower (DSKYF) Seeking Alpha

Daiichi Sankyo, with tighter focus on oncology, sells 8 aging US cardiovascular drugs to diversifying Cosette Fierce Pharma

Daiichi Sankyo is Embarking on Mission Possible BioSpace

Nexletol partners Esperion and Daiichi Sankyo patch up milestone dispute with $125M settlement Fierce Pharma

Nosis Biosciences Announces Research Collaboration and Option Agreement with Daiichi Sankyo to Develop Cell-Targeted RNA Medicines Business Wire

AstraZeneca, Daiichi Sankyo Win First Tumor-Agnostic HER2 FDA Approval for Enhertu BioSpace

Daiichi Sankyo and Merck Enter into Global Development and Commercialization Agreement for MK-6070 Business Wire

Daiichi Sankyo and Merck Announce Global Development and Commercialization Collaboration for Three Daiichi Sankyo DXd ADCs Business Wire

Daiichi Sankyo poaches Kite's research lead Takeshita from parent Gilead Fierce Biotech

Daiichi Sankyo taps CRO Syneos Health to help run ADC cancer drug work, including Enhertu Fierce Biotech

US agency nixes Seagen patent, handing Daiichi Sankyo a win in long-running Enhertu entanglement Fierce Pharma

Daiichi Sankyo inks $200M licensing deal with Ultragenyx to boost gene therapy manufacturing Fierce Pharma

"No Clear Response" Ends Early-Stage Daiichi Sankyo ADC Program BioSpace

AstraZeneca puts $6.9B on the table for a Daiichi Sankyo cancer drug Fierce Biotech

Daiichi Sankyo wades deeper into oncology with FDA go-ahead in rare joint cancer Fierce Pharma

Daiichi Sankyo rises most in five months on cancer drug approval The Japan Times

Global pharma giant AstraZeneca strikes $6.9 billion deal to expand cancer portfolio CNBC

Daiichi Sankyo beats Honda in market cap on cancer drug ambitions Nikkei Asia

AZ, Daiichi's new cancer drug Enhertu gets off to the races with quick U.S. launch Fierce Pharma

Daiichi Sankyo eyes newer cancer drugs to stave off rivals The Japan Times

Despite phase 2 miss, Daiichi Sankyo wants Glycotope lead antibody for cancer ADC Fierce Biotech

Japan's Daiichi Sankyo to make cutting-edge cancer treatments in China Nikkei Asia

Daiichi Sankyo settles U.S. lawsuits over blood pressure drug Benicar Reuters

Japan's Daiichi Sankyo to export vaccines to Southeast Asia by 2030 Nikkei Asia

IHH Healthcare unit files $179.5m lawsuit against Daiichi Sankyo over Fortis deal The Straits Times

Daiichi Sankyo's disastrous India foray with hybrid model Business Today